ClinicalTrials.gg
CompletedNCT06140771Updated Nov 20, 2023

A Clinical Study to Assess the Gingivitis Effects of Various Dentifrices

An interventional study of 0.76% Sodium Monofluorophosphate Dentifrice and 1.15% Sodium Monofluorophosphate Dentifrice in Gingivitis, sponsored by Procter and Gamble. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-20.

Sponsored by Procter and Gamble · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Oct 2021, registered Nov 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing Tin Fluorides in Gingivitis — 1 open to participants now, 3 under way, none of them phase 3. Tin Fluorides · Gingivitis.

Enrollment
12th of 23
115 · median 115
Started
2021
with 1 other
No phase
10 of 23
none open now
Registered
14th of 23
by date
Lead sponsor
9 of 23
Procter and Gamble

Among the 23 studies testing Tin Fluorides in Gingivitis, this one is the 12th largest by enrollment, is one of 2 that started in 2021, is one of 10 with no phase, and was the 14th registered.

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

Browse Gingivitis studies →

Open to participants now

1 of the 23 studies testing Tin Fluorides in Gingivitis is open now. Recruiting first, the newest first:

About Tin Fluorides

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing Tin Fluorides in Gingivitis, or all of them as a file.
02

Study summary

The objective of this learning clinical study is to assess the gingivitis effects of four different dentifrices over a 3-month period.

03

Conditions studied

  • Gingivitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 18 years of age;
  • Provide written prior to participation and be given a signed copy of the informed consent form;
  • Be in general good health as determined by the Investigator based on a review of the health history/update for participation in the trial;
  • Have at least 16 gradable teeth;
  • Have mild to moderate gingivitis with a range of 10% to 70% bleeding sites;
  • Agree to return for scheduled visits and follow the study procedures;
  • Agree to refrain from use of any non-study oral hygiene products for the duration of the study;
  • Agree to delay any elective dentistry, including dental prophylaxis, until the completion of the study.

Exclusion criteria

Exclusion Criteria:

  • Having taken antibiotic, anti-inflammatory, or anti-coagulant medications within 4 weeks of the Baseline Visit;
  • Have any oral conditions that could interfere with study compliance and/or examination procedures, such as widespread caries, soft or hard tissue tumor of the oral cavity, or advanced periodontal disease;
  • Removable oral appliances;
  • Fixed facial or lingual orthodontic appliances;
  • Self-reported pregnancy or lactation;
  • Any diseases or condition that might interfere with the safe participation in the study; and
  • Inability to undergo study procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
115 participants (actual)

Study arms

  • Sham comparator
    0.76% Sodium Monofluorophosphate Dentifrice

    Drug: 0.76% Sodium Monofluorophosphate Dentifrice

  • Sham comparator
    1.15% Sodium Monofluorophosphate Dentifrice

    Drug: 1.15% Sodium Monofluorophosphate Dentifrice

  • Active comparator
    Marketed 0.454% Stannous Fluoride Dentifrice

    Drug: 0.454% Stannous Fluoride Dentifrice

  • Active comparator
    0.454% Stannous Fluoride Dentifrice

    Drug: 0.454% Stannous Fluoride Dentifrice

Interventions

  • Drug0.76% Sodium Monofluorophosphate Dentifrice

    Whole mouth brushing with a toothpaste, twice daily for the duration of the study.

  • Drug1.15% Sodium Monofluorophosphate Dentifrice

    Whole mouth brushing with a toothpaste, twice daily for the duration of the study.

  • Whole mouth brushing with a toothpaste, twice daily for the duration of the study.

  • Whole mouth brushing with a toothpaste, twice daily for the duration of the study.

06

What researchers measure

Primary outcomes

  1. Löe-Silness Gingivitis Evaluation

    Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).

    Time frame: 3 Months

Secondary outcomes

  1. Löe-Silness Gingivitis Evaluation

    Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).

    Time frame: Baseline

  2. Löe-Silness Gingivitis Evaluation

    Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).

    Time frame: 1 Month

07

Study locations

1 site
  • UHRG
    Whittier, California 90602, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Feb 2022, 3 months.

Of 53 industry-sponsored interventional studies with no phase under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 5. This study's 3 months is close to that.

Counting every sponsor, half of 257 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2023
First posted
Nov 20, 2023
StartActual
Oct 20, 2021
Primary completionActual
Feb 6, 2022
CompletionActual
Feb 6, 2022
Last update
Nov 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06140771
Lead sponsor
Procter and Gamble
Responsible party
Sponsor
First posted
Nov 20, 2023
Start date
Oct 20, 2021
Primary completion
Feb 6, 2022
Completion
Feb 6, 2022
Last update
Nov 20, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tin Fluorides

Start the discussion